You are here: Industry Insights > NIH

News List

Moderna Highlights Publication of Antibody Persistence Data of its COVID-19 Vaccine out to 6 Months in the New England Journal of Medicine americanpharmaceuticalreview
April 12, 2021
Moderna, Inc. highlighted the publication of antibody persistence data out to 6 months following the second dose of the Moderna COVID-19 Vaccine in The New England Journal of Medicine.
Mologic’s COVID-19 Rapid Antigen Self-Test Selected by NIH for RADx Initiative Funding americanpharmaceuticalreview
April 09, 2021
Mologic announced its rapid antigen self-test for COVID-19 has been selected by the Rapid Acceleration of Diagnostics (RADxSM) initiative launched by the U.S. National Institutes of Health (NIH).
Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment contractpharma
April 08, 2021
Sound Pharmaceuticals, Inc. (SPI) has received a Cooperative Grant award from the National Center for Advancing Translational Sciences (NCATS) at the NIH for $3.1 milion to support the testing of SPI-1005 in two Phase 2 clinical trials for the ...
NIH begins trial of Moderna’s Covid-19 variant vaccine pharmaceutical-technology
April 02, 2021
The US National Institutes of Health (NIH) has initiated dosing in a new Phase I clinical trial of Moderna’s investigational vaccine candidate, mRNA-1273.351, in adult subjects.
NIH-funded study finds evidence that SARS-CoV-2 infects cells in mouth pharmaceutical-technology
March 29, 2021
A team led by scientists at the National Institutes of Health (NIH) and the University of North Carolina (UNC) at Chapel Hill in the US has found evidence that SARS-CoV-2, which causes Covid-19, infects cells in the mouth.
US health agency questions AstraZeneca’s Covid-19 vaccine trial data pharmaceutical-technology
March 24, 2021
US health officials have questioned the validity of AstraZeneca’s most recent vaccine trial results, saying the data provided by the company may be “outdated”.
Rigel concludes subject enrolment in NIH-sponsored Covid-19 trial pharmaceutical-technology
March 15, 2021
Rigel Pharmaceuticals has concluded patient enrolment in a Phase II clinical trial of its oral spleen tyrosine kinase (SYK) inhibitor, fostamatinib, for treating hospitalised Covid-19 patients.
NIAID grants $2.5m to 12 institutes for bacteriophage therapy research pharmaceutical-business-review
March 12, 2021
A branch of the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID) has granted $2.5m to 12 institutes across the world for bacteriophage therapy research.
NIH launches last trial of anticoagulant treatments for Covid-19 pharmaceutical-technology
March 10, 2021
The US National Institutes of Health (NIH) has initiated the last of three Phase III clinical trials of blood thinners (anticoagulant) to prevent life-threatening blood clots in adults with Covid-19.
US closes enrolment in two COVID-19 antibody studies due to futility europeanpharmaceuticalreview
March 08, 2021
The sub-studies evaluating VIR-7831 and BRII-196 with BRII-198 have stopped enrolment based on recommendations from the Data and Safety Monitoring Board.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page